SCHEMBL2893565

SCHEMBL2893565

O=C(O)c1sc2ccccc2c1F

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 5/20 0.62
PRNP P04156 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
LIMK1 P53667 2/20 0.49
IKBKB O14920 1/20 0.49
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
MAPK1 P28482 2/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
LMNA P02545 1/20 0.45
EDNRA P25101 1/20 0.44
OGG1 O15527 1/20 0.44
BCKDK O14874 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16599116 0.86 LIMK1 (0.50) MCL1PRNPRXFP1LIMK1IKBKB
SCHEMBL120330 0.80 MCL1 (0.45) MCL1LIMK1BCKDKMEN1KMT2A
SCHEMBL647033 0.78 MCL1 (0.65) MCL1PRNPRXFP1LIMK1IKBKB
SCHEMBL941112 0.78 MCL1 (0.65) MCL1PRNPRXFP1LIMK1IKBKB
SCHEMBL29664668 0.78 MCL1 (0.65) MCL1PRNPRXFP1LIMK1IKBKB
SCHEMBL20559686 0.78 BCKDK (0.71) MCL1RXFP1LMNABCKDKKDM4E
SCHEMBL1919937 0.77 LIMK1 (0.73) MCL1PRNPRXFP1LIMK1IKBKB
SCHEMBL346530 0.77 MCL1 (0.62) MCL1PRNPRXFP1LIMK1IKBKB
SCHEMBL584871 0.77 RXFP1 (0.71) MCL1PRNPRXFP1LIMK1IKBKB
SCHEMBL444722 0.77 MCL1 (1.00) MCL1RXFP1MAPK1HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227423-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2023-07-20 US disclosed
US-11613525-B2 Substituted condensed thiophenes as modulators of sting CTXT PTY LIMITED (AU) 2023-03-28 US disclosed
US-20210214333-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD. (AU) 2021-07-15 US disclosed
CN-109054648-A Serosity combination for chemically mechanical polishing LTCAM有限公司 2018-12-21 CN disclosed
CN-109071374-A The arylation of fatty amine AAA化学公司 2018-12-21 CN disclosed
CN-105263926-B Benzothienyl compounds 安斯泰来制药株式会社 2018-05-11 CN disclosed
WO-2016191366-A1 MODULATORS FOR NICOTINIC ACETYLCHOLINE RECEPTOR α2 AND α4 SUBUNITS THE SCRIPPS RESEARCH INSTITUTE (US) 2016-12-01 WO disclosed
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 US disclosed
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 US disclosed
US-8884017-B2 2-heteroarylcarboxylic acid amides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-11-11 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
EP-2720695-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NoNO Inc. (CA) 2014-04-23 EP disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed
US-20120202842-A1 2-HETEROARYLCARBOXYLIC ACID AMIDES BAYER SCHERING PHARMA AG (DE) 2012-08-09 US disclosed
US-8076355-B2 2-heteroarylcarboxylic acid amides BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-12-13 US disclosed
US-20100222378-A1 2-HETEROARYLCARBOXYLIC ACID AMIDES BAYER SCHERING PHARMA AG (DE) 2010-09-02 US disclosed
US-7732477-B2 N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-08 US disclosed
EP-1461335-B1 2-HETEROARYLCARBOXYLIC ACID AMIDES BAYER HEALTHCARE AG (DE) 2007-02-28 EP disclosed
US-20050119325-A1 N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain FMR LLC 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227423-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING STING1, CGAS, IRF3 MCL1 1773/4885PRNP 4624/4885RXFP1 460/4885
US-20100222378-A1 2-HETEROARYLCARBOXYLIC ACID AMIDES HCAR2, HCAR1, GRIN2A MCL1 3543/4885PRNP 3164/4885RXFP1 3343/4885
US-20210214333-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING STING1, CGAS, IRF3 MCL1 1851/4885PRNP 4632/4885RXFP1 413/4885
US-20050119325-A1 N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain CHRNA2, CHRNA7, CHRNA3 MCL1 3305/4885PRNP 3943/4885RXFP1 1074/4885
US-11613525-B2 Substituted condensed thiophenes as modulators of sting STING1, CGAS, IRF3 MCL1 1851/4885PRNP 4632/4885RXFP1 413/4885
US-20120202842-A1 2-HETEROARYLCARBOXYLIC ACID AMIDES HCAR2, HCAR1, GRIN2A MCL1 3543/4885PRNP 3164/4885RXFP1 3343/4885
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 MCL1 3339/4885PRNP 4610/4885RXFP1 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.